Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nuvectis Pharma, Inc. - Common Stock
(NQ:
NVCT
)
6.400
+0.210 (+3.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nuvectis Pharma, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
September 06, 2023
Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
September 01, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
August 17, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
10 Short Squeeze Stocks To Watch: Blue Apron, Intuitive Machines, Yellow Corp, Getty Images And More
August 14, 2023
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move. High short interest and steep borrowing costs are among...
Via
Benzinga
Insiders Buying Texas Capital Bancshares And 3 Other Stocks
July 28, 2023
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
Insiders Buying Steel Connect And 2 Other Stocks
July 21, 2023
Although US stocks closed mixed on Thursday, there were a few notable insider trades.
Via
Benzinga
Insiders Buying Nuvectis Pharma And 2 Other Stocks
July 20, 2023
Although US stocks closed mostly higher on Wednesday, there were a few notable insider trades.
Via
Benzinga
Insiders Buying Joint Corp And 2 Other Stocks
July 19, 2023
Although US stocks closed higher on Tuesday, there were a few notable insider trades.
Via
Benzinga
Insiders Buying BranchOut Food And 2 Other Stocks
July 14, 2023
Although US stocks closed higher for the fourth session in a row, there were a few notable insider trades.
Via
Benzinga
Insiders Buying Asana And 2 Other Stocks
July 13, 2023
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock....
Via
Benzinga
More Than $3M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying
July 11, 2023
Although US stocks closed higher on Monday, there were a few notable insider trades.
Via
Benzinga
$1M Bet On Children's Place? Check Out These 3 Stocks Insiders Are Buying
July 07, 2023
Although US stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
June 20, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Over $2M Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying
June 20, 2023
Although US stocks closed lower on Friday, there were a few notable insider trades.
Via
Benzinga
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
May 15, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
April 27, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
April 27, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
April 18, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
April 10, 2023
Phase 1b study builds on highly consistent preclinical and Phase 1a data
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
March 17, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
March 10, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
February 23, 2023
Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to treatment with cisplatin
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
January 04, 2023
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
December 01, 2022
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
October 03, 2022
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma Announces Formation of a Scientific Advisory Board
September 28, 2022
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
July 27, 2022
From
Nuvectis Pharma, Inc.
Via
GlobeNewswire
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
July 27, 2022
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
July 13, 2022
Upgrades
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.